Vir Biotechnology, Inc. (VIR)
10.71
+0.80
(+8.07%)
USD |
NASDAQ |
Aug 25, 16:00
10.80
+0.09
(+0.84%)
Pre-Market: 08:27
Vir Biotechnology Debt to Equity Ratio : 0.0949 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0949 |
| March 31, 2026 | 0.1176 |
| December 31, 2025 | 0.1279 |
| September 30, 2025 | 0.1258 |
| June 30, 2025 | 0.1079 |
| March 31, 2025 | 0.0921 |
| December 31, 2024 | 0.0851 |
| September 30, 2024 | 0.0909 |
| June 30, 2024 | 0.0799 |
| March 31, 2024 | 0.0783 |
| December 31, 2023 | 0.0783 |
| September 30, 2023 | 0.0762 |
| June 30, 2023 | 0.0726 |
| March 31, 2023 | 0.0653 |
| December 31, 2022 | 0.0616 |
| September 30, 2022 | 0.061 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.0688 |
| March 31, 2022 | 0.0684 |
| December 31, 2021 | 0.096 |
| September 30, 2021 | 0.0823 |
| June 30, 2021 | 0.0983 |
| March 31, 2021 | 0.1078 |
| December 31, 2020 | 0.0992 |
| September 30, 2020 | 0.0203 |
| June 30, 2020 | 0.0301 |
| March 31, 2020 | 0.0466 |
| December 31, 2019 | 0.0027 |
| September 30, 2019 | -2.271 |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Caribou Biosciences, Inc. | 0.2717 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.215B |
| Total Liabilities (Quarterly) | 232.31M |
| Shareholders Equity (Quarterly) | 982.49M |
| Current Ratio | 6.042 |
| Net Debt Paydown Yield | 0.03% |